{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:31:02Z","timestamp":1774085462835,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We focused on Differentiated pseudoprogression (PPN) of progression (PN) and the response to radiotherapy (RT) or chemoradiotherapy (CRT) using diffusion and metabolic imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy-five patients with glioma were included in this prospective study (approved by the Iranian Registry of Clinical Trials (IRCT) (IRCT20230904059352N1) in September 2023). Contrast-enhanced lesion volume (CELV), non-enhanced lesion volume (NELV), necrotic tumor volume (NTV), and quantitative values \u200b\u200bof apparent diffusion coefficient (ADC) and magnetic resonance spectroscopy (Cho\/Cr, Cho\/NAA and NAA\/Cr) were calculated by a neuroradiologist using a semi-automatic method. All patients were followed at one and six months after CRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results of the study showed statistically significant changes before and six months after RT-CRT for M-CELV in all glioma types (\ud835\udc5d &lt; 0.05). In glioma cell types, the changes in M-ADC, M-Cho\/Cr, and Cho\/NAA indices for PN were incremental and greater for PPN patients. M-NAA\/Cr ratio decreased after six months which was significant only on PN for GBM, and Epn (\ud835\udc5d &lt; 0.05). A significant difference was observed between diffusion indices, metabolic ratios, and CELV changes after six months in all types (\ud835\udc5d &lt; 0.05). None of the patients were suspected PPN one month after treatment. The DWI\/ADC indices had higher sensitivity and specificity (98.25% and 96.57%, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results of the present study showed that ADC values and Cho\/Cr and Cho\/NAA ratios can be used to differentiate between patients with PPN and PN, although ADC is more sensitive and specific.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-023-01135-x","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T12:01:49Z","timestamp":1699272109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-chemo-radiotherapy response and pseudo-progression evaluation on glioma cell types by multi-parametric magnetic resonance imaging: a prospective study"],"prefix":"10.1186","volume":"23","author":[{"given":"Maryam","family":"Zamanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraj","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Danazadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Amouheidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bentolhoda Otroshi","family":"Shahreza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"1135_CR1","first-page":"1","volume":"1","author":"M Weller","year":"2015","unstructured":"Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma Nat Rev Dis. 2015;1:1\u201318.","journal-title":"Glioma Nat Rev Dis"},{"key":"1135_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10014-018-0309-0","volume":"35","author":"T Iuchi","year":"2018","unstructured":"Iuchi T, Sugiyama T, Ohira M, Kageyama H, Yokoi S, Sakaida T, et al. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 2018;35:71\u201380. https:\/\/doi.org\/10.1007\/s10014-018-0309-0.","journal-title":"Brain Tumor Pathol"},{"key":"1135_CR3","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/jco.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncology: Official J Am Soc Clin Oncol. 2010;28:1963\u201372. https:\/\/doi.org\/10.1200\/jco.2009.26.3541.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1135_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-319-12048-5_4","volume":"163","author":"IJ Barani","year":"2015","unstructured":"Barani IJ, Larson DA. Radiation therapy of glioblastoma. Cancer Treat Res. 2015;163:49\u201373. https:\/\/doi.org\/10.1007\/978-3-319-12048-5_4.","journal-title":"Cancer Treat Res"},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/jco.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology clinical trials. J Clin Oncol. 2017;35:2439\u201349. https:\/\/doi.org\/10.1200\/jco.2017.72.7511.","journal-title":"J Clin Oncol"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/neuonc\/noq203","volume":"13","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011;13:353\u201361. https:\/\/doi.org\/10.1093\/neuonc\/noq203.","journal-title":"Neuro Oncol"},{"key":"1135_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1212\/wnl.38.5.724","volume":"38","author":"JG Cairncross","year":"1988","unstructured":"Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology. 1988;38:724\u20136. https:\/\/doi.org\/10.1212\/wnl.38.5.724.","journal-title":"Neurology"},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/s1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315\u2013e29. https:\/\/doi.org\/10.1016\/s1470-2045(17)30194-8.","journal-title":"Lancet Oncol"},{"key":"1135_CR9","doi-asserted-by":"publisher","first-page":"Cns28","DOI":"10.2217\/cns-2018-0007","volume":"8","author":"UN Chukwueke","year":"2019","unstructured":"Chukwueke UN, Wen PY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8:Cns28. https:\/\/doi.org\/10.2217\/cns-2018-0007.","journal-title":"CNS Oncol"},{"key":"1135_CR10","first-page":"14","volume":"3","author":"FI Fitri","year":"2022","unstructured":"Fitri FI, Lubis ND, Darman WR, Fithrie A. Correlation between Response Assessment in Neuro-Oncology (RANO) Criteria and clinical outcome in patients with Brain Tumor. J Health sci Medicine. 2022;3:14\u201320.","journal-title":"J Health sci Medicine"},{"key":"1135_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3174\/ajnr.A6358","volume":"41","author":"DJ Leao","year":"2020","unstructured":"Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B. Response Assessment in Neuro-Oncology Criteria for Gliomas: practical Approach using Conventional and Advanced techniques. AJNR Am J Neuroradiol. 2020;41:10\u201320. https:\/\/doi.org\/10.3174\/ajnr.A6358.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1135_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/nop\/npv037","volume":"2","author":"SM Chang","year":"2015","unstructured":"Chang SM, Wen PY, Vogelbaum MA, Macdonald DR, van den Bent MJ. Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma. Neurooncol Pract. 2015;2:205\u20139. https:\/\/doi.org\/10.1093\/nop\/npv037.","journal-title":"Neurooncol Pract"},{"key":"1135_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-015-1774-5","volume":"123","author":"I Melguizo-Gavilanes","year":"2015","unstructured":"Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015;123:141\u201350. https:\/\/doi.org\/10.1007\/s11060-015-1774-5.","journal-title":"J Neurooncol"},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/neuonc\/now194","volume":"19","author":"SE van West","year":"2017","unstructured":"van West SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, van den Bent MJ, Taal W. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. Neurooncology. 2017;19:719\u201325. https:\/\/doi.org\/10.1093\/neuonc\/now194.","journal-title":"Neurooncology"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00062-017-0584-x","volume":"28","author":"AW Abbasi","year":"2018","unstructured":"Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A. Incidence of Tumour Progression and Pseudoprogression in High-Grade gliomas: a systematic review and Meta-analysis. Clin Neuroradiol. 2018;28:401\u201311. https:\/\/doi.org\/10.1007\/s00062-017-0584-x.","journal-title":"Clin Neuroradiol"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"6828396","DOI":"10.1155\/2018\/6828396","volume":"2018","author":"A Zikou","year":"2018","unstructured":"Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor recurrence: Imaging challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018;2018:6828396. https:\/\/doi.org\/10.1155\/2018\/6828396.","journal-title":"Contrast Media Mol Imaging"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.acra.2021.11.008","volume":"29","author":"A Feng","year":"2022","unstructured":"Feng A, Yuan P, Huang T, Li L, Lyu J. Distinguishing Tumor Recurrence from Radiation necrosis in treated Glioblastoma using Multiparametric MRI. Acad Radiol. 2022;29:1320\u201331. https:\/\/doi.org\/10.1016\/j.acra.2021.11.008.","journal-title":"Acad Radiol"},{"key":"1135_CR18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ijrobp.2014.06.015","volume":"90","author":"CJ Perez-Torres","year":"2014","unstructured":"Perez-Torres CJ, Engelbach JA, Cates J, Thotala D, Yuan L, Schmidt RE, et al. Toward distinguishing recurrent Tumor from radiation necrosis: DWI and MTC in a Gamma Knife\u2013irradiated mouse glioma model. Int J Radiat Oncol Biol Phys. 2014;90:446\u201353. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.06.015.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1135_CR19","doi-asserted-by":"publisher","first-page":"e1059","DOI":"10.1016\/j.wneu.2021.05.064","volume":"151","author":"S Travers","year":"2021","unstructured":"Travers S, Joshi K, Miller DC, Singh A, Nada A, Biedermann G, et al. Reliability of Magnetic Resonance Spectroscopy and Positron Emission Tomography Computed Tomography in differentiating metastatic Brain Tumor recurrence from Radiation Necrosis. World Neurosurg. 2021;151:e1059\u2013e68. https:\/\/doi.org\/10.1016\/j.wneu.2021.05.064.","journal-title":"World Neurosurg"},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"20170930","DOI":"10.1259\/bjr.20170930","volume":"91","author":"P Seow","year":"2018","unstructured":"Seow P, Wong JHD, Ahmad-Annuar A, Mahajan A, Abdullah NA, Ramli N. Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review. Br J Radiol. 2018;91:20170930. https:\/\/doi.org\/10.1259\/bjr.20170930.","journal-title":"Br J Radiol"},{"key":"1135_CR21","doi-asserted-by":"publisher","first-page":"20180088","DOI":"10.1259\/bjr.20180088","volume":"91","author":"K Aslan","year":"2018","unstructured":"Aslan K, Gunbey HP, Tomak L, Incesu L. The diagnostic value of using combined MR diffusion tensor imaging parameters to differentiate between low- and high-grade meningioma. Br J Radiol. 2018;91:20180088. https:\/\/doi.org\/10.1259\/bjr.20180088.","journal-title":"Br J Radiol"},{"key":"1135_CR22","doi-asserted-by":"publisher","first-page":"20200009","DOI":"10.1259\/bjro.20200009","volume":"2","author":"G Abdalla","year":"2020","unstructured":"Abdalla G, Hammam A, Anjari M, D\u2019Arco DF, Bisdas DS. Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook. BJR open. 2020;2:20200009. https:\/\/doi.org\/10.1259\/bjro.20200009.","journal-title":"BJR open"},{"key":"1135_CR23","doi-asserted-by":"publisher","first-page":"6616992","DOI":"10.1155\/2021\/6616992","volume":"2021","author":"Z Alirezaei","year":"2021","unstructured":"Alirezaei Z, Amouheidari A, Hassanpour M, Davanian F, Iraji S, Shokrani P, et al. Early detection of Radiation-Induced Injury and Prediction of Cognitive Deficit by MRS metabolites in Radiotherapy of Low-Grade Glioma. Biomed Res Int. 2021;2021:6616992. https:\/\/doi.org\/10.1155\/2021\/6616992.","journal-title":"Biomed Res Int"},{"key":"1135_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jocn.2020.11.030","volume":"83","author":"X Hu","year":"2021","unstructured":"Hu X, Xue M, Sun S, Zou Y, Li J, Wang X, et al. Combined application of MRS and DWI can effectively predict cell proliferation and assess the grade of glioma: a prospective study. J Clin Neurosci. 2021;83:56\u201363. https:\/\/doi.org\/10.1016\/j.jocn.2020.11.030.","journal-title":"J Clin Neurosci"},{"key":"1135_CR25","doi-asserted-by":"publisher","unstructured":"Zhang S, Cao J, Ahn C. A GEE Approach to determine sample size for pre- and Post-intervention experiments with dropout. Comput Stat Data Anal. 2014;69. https:\/\/doi.org\/10.1016\/j.csda.2013.07.037.","DOI":"10.1016\/j.csda.2013.07.037"},{"key":"1135_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/neuonc\/noq049","volume":"12","author":"IS Khayal","year":"2010","unstructured":"Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, et al. Evaluation of diffusion parameters as early biomarkers of Disease progression in Glioblastoma Multiforme. Neuro Oncol. 2010;12:908\u201316. https:\/\/doi.org\/10.1093\/neuonc\/noq049.","journal-title":"Neuro Oncol"},{"key":"1135_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.acra.2012.06.011","volume":"19","author":"WJ Lee","year":"2012","unstructured":"Lee WJ, Choi SH, Park CK, Yi KS, Kim TM, Lee SH, et al. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. Acad Radiol. 2012;19:1353\u201361. https:\/\/doi.org\/10.1016\/j.acra.2012.06.011.","journal-title":"Acad Radiol"},{"key":"1135_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3174\/ajnr.A4218","volume":"36","author":"AJ Prager","year":"2015","unstructured":"Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol. 2015;36:877\u201385. https:\/\/doi.org\/10.3174\/ajnr.A4218.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1135_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1148\/radiol.13122024","volume":"269","author":"HH Chu","year":"2013","unstructured":"Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, et al. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology. 2013;269:831\u201340. https:\/\/doi.org\/10.1148\/radiol.13122024.","journal-title":"Radiology"},{"key":"1135_CR30","doi-asserted-by":"publisher","first-page":"641023","DOI":"10.1155\/2015\/641023","volume":"2015","author":"M Bulik","year":"2015","unstructured":"Bulik M, Kazda T, Slampa P, Jancalek R. The diagnostic ability of Follow-Up imaging biomarkers after Treatment of Glioblastoma in the Temozolomide era: implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping. Biomed Res Int. 2015;2015:641023. https:\/\/doi.org\/10.1155\/2015\/641023.","journal-title":"Biomed Res Int"},{"key":"1135_CR31","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3174\/ajnr.A6499","volume":"41","author":"S Vajapeyam","year":"2020","unstructured":"Vajapeyam S, Brown D, Billups C, Patay Z, Vezina G, Shiroishi MS, et al. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in newly diagnosed diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. AJNR Am J Neuroradiol. 2020;41:718\u201324. https:\/\/doi.org\/10.3174\/ajnr.A6499.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1135_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/jmri.26900","volume":"51","author":"J Liu","year":"2020","unstructured":"Liu J, Li C, Chen Y, Lv X, Lv Y, Zhou J, et al. Diagnostic performance of multiparametric MRI in the evaluation of treatment response in glioma patients at 3T. J Magn Reson Imaging. 2020;51:1154\u201361. https:\/\/doi.org\/10.1002\/jmri.26900.","journal-title":"J Magn Reson Imaging"},{"key":"1135_CR33","first-page":"301","volume":"15","author":"F Allahmoradi","year":"2018","unstructured":"Allahmoradi F, Haghparast A, Zakariaee SS, Naleini F. Role of apparent diffusion coefficient value in Diffusion Weighted imaging of MRI to assessment of radiotherapy efficiency in the patient with glioma Tumor during treatment. Iran J Med Phys. 2018;15:301.","journal-title":"Iran J Med Phys"},{"key":"1135_CR34","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3174\/ajnr.A4428","volume":"36","author":"R Ceschin","year":"2015","unstructured":"Ceschin R, Kurland BF, Abberbock SR, Ellingson BM, Okada H, Jakacki RI, et al. Parametric Response Mapping of Apparent Diffusion Coefficient as an imaging biomarker to Distinguish Pseudoprogression from true Tumor progression in peptide-based vaccine therapy for Pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2015;36:2170\u20136. https:\/\/doi.org\/10.3174\/ajnr.A4428.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1135_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/RLI.0b013e31820e1511","volume":"46","author":"J V\u00f6glein","year":"2011","unstructured":"V\u00f6glein J, T\u00fcttenberg J, Weimer M, Gerigk L, Kauczor HU, Essig M, et al. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest Radiol. 2011;46:390\u2013400. https:\/\/doi.org\/10.1097\/RLI.0b013e31820e1511.","journal-title":"Invest Radiol"},{"key":"1135_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.31661\/jbpe.v0i0.1224","volume":"12","author":"H Mohammadi","year":"2022","unstructured":"Mohammadi H, Changizi V, Riyahi Alam N, Rahiminejad F, Soleimani M, Qardashi A. Measurement of Post-treatment Changes in Brain metabolites in patients with generalized anxiety disorder using magnetic resonance spectroscopy. J Biomed Phys Eng. 2022;12:51\u201360. https:\/\/doi.org\/10.31661\/jbpe.v0i0.1224.","journal-title":"J Biomed Phys Eng"},{"key":"1135_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/197140091202500511","volume":"25","author":"V Sawlani","year":"2012","unstructured":"Sawlani V, Taylor R, Rowley K, Redfern R, Martin J, Poptani H. Magnetic resonance spectroscopy for differentiating pseudo-progression from true progression in GBM on Concurrent Chemoradiotherapy. Neuroradiol J. 2012;25:575\u201386. https:\/\/doi.org\/10.1177\/197140091202500511.","journal-title":"Neuroradiol J"},{"key":"1135_CR38","doi-asserted-by":"publisher","first-page":"e4042","DOI":"10.1002\/nbm.4042","volume":"32","author":"G Verma","year":"2019","unstructured":"Verma G, Chawla S, Mohan S, Wang S, Nasrallah M, Sheriff S, et al. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. NMR Biomed. 2019;32:e4042. https:\/\/doi.org\/10.1002\/nbm.4042.","journal-title":"NMR Biomed"},{"key":"1135_CR39","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/jmri.26702","volume":"50","author":"JE Meissner","year":"2019","unstructured":"Meissner JE, Korzowski A, Regnery S, Goerke S, Breitling J, Floca RO, et al. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T. J Magn Reson Imaging. 2019;50:1268\u201377. https:\/\/doi.org\/10.1002\/jmri.26702.","journal-title":"J Magn Reson Imaging"},{"key":"1135_CR40","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.ejrad.2015.09.005","volume":"84","author":"A Lotumolo","year":"2015","unstructured":"Lotumolo A, Caivano R, Rabasco P, Iannelli G, Villonio A, D\u2019Antuono F, et al. Comparison between magnetic resonance spectroscopy and diffusion weighted imaging in the evaluation of gliomas response after treatment. Eur J Radiol. 2015;84:2597\u2013604.","journal-title":"Eur J Radiol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-023-01135-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-023-01135-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-023-01135-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T12:02:56Z","timestamp":1699272176000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-023-01135-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1186\/s12880-023-01135-x","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Isfahan University of Medical Sciences on 2022-02-23 under (IR.ARI.MUI.REC.1400.099 (code. The condition of the study was explained to patients and the written informed consent was signed by the patients (or legal guardians of the patients under 16 years of age). All the steps have been approved in advance and according to the doctor\u2019s opinion, it was necessary to change the protocol for the health of the patient, left the study, and have another treatment procedure performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}